Core pharmacology

Class Group

Antiplatelet

Legacy Cicm Level

Level 3

Introduction

GP IIb/IIIA Inhibitor

Main Action

Platelet inhibition

Mechanism of action

Antagonises the GpIIb/IIIa
receptor, preventing the
binding of fibrinogen and
platelet crosslinking and
aggregation.

Adverse Effects Toxicity

Haemorrhage
Difficulty reversing agent
Dose adjustment in renal impairment

Metabolism

Limited metabolism in humans.

Excretion

Excreted in urine and faeces, mostly
unchanged

Half-life

HL 1.9-2.2 hrs